Molnupiravir is an investigational oral antiviral agent, currently being studied in a Phase 3 trial for the treatment of non-hospitalised patients with confirmed Covid-19.

Molnupiravir is an investigational oral antiviral agent, currently being studied in a Phase 3 trial for the treatment of non-hospitalised patients with confirmed Covid-19.